कीमोथेरेपी: ओपन एक्सेस
खुला एक्सेस

अमूर्त

Epithelial Ovarian Cancers: On-Target is Better than Near-Target

Joydeep Ghosh and Jyoti Bajpai

Epithelial ovarian cancer is the most common cause of gynecological cancer-related mortality worldwide. The discovery that PARP inhibitors block an essential DNA repair pathway in BRCA mutant cells has revolutionized the management of high-grade ovarian cancers. The cross talk among PARP inhibitors and other molecularly targeted therapies such as anti angiogenic drugs further broadens the scope of these agents. A paradigm shift in the management of ovarian cancer is rapidly emerging, potentiated by a better understanding of the underlying defective molecular pathways/mechanisms.

This is providing the opportunity for the clinicians to deliver an effective, yet less toxic and durable treatment to a molecularly selected patient population.